--- title: "Mid-Cap US Equities Diverge: Charles River Raises Forecast as Tech Firms Weigh Restructuring" type: "News" locale: "en" url: "https://longbridge.com/en/news/295081428.md" description: "Niche US equities are charting distinct paths in 2026. Healthcare and financial firms like Charles River Laboratories and StoneX Group are posting robust growth and raising guidance, while tech operators such as Jet.AI accelerate restructuring efforts." datetime: "2026-08-06T09:15:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295081428.md) - [en](https://longbridge.com/en/news/295081428.md) - [zh-HK](https://longbridge.com/zh-HK/news/295081428.md) generator: "portal-rs" --- # Mid-Cap US Equities Diverge: Charles River Raises Forecast as Tech Firms Weigh Restructuring Niche US equities are charting increasingly divergent paths in mid-2026. According to recent filings and market data, leaders in the life sciences and financial services sectors are raising full-year forecasts on the back of resilient demand, while smaller tech and mobility players are navigating complex structural overhauls. ### Charles River Laboratories (CRL.US) & Healthcare Charles River Laboratories (CRL.US) has recently outperformed the broader sector, reporting second-quarter 2026 revenue of **USD 1.0 billion** and an adjusted earnings per share (EPS) of USD 3.02, both topping Wall Street estimates. While the top line contracted by 2.7% on an annualized basis, the 0.1% uptick in organic sales ended a streak of declines stretching back to late 2023. The company noted a robust demand recovery in its Discovery and Safety Assessment (DSA) segment, where the book-to-bill ratio climbed to 1.19x—the highest in nearly four years. The print prompted JPMorgan to upgrade the stock to overweight with a USD 310 price target, as management’s decision to raise its full-year forecast to a median adjusted EPS of USD 11.30 signaled growing confidence. In the broader biotechnology space, early-stage operators Medicus Pharma (MDCX.US) and Regentis Biomaterials (RGNT.US) are concurrently attempting to anchor market expectations by advancing their respective clinical pipelines amid a shifting macro backdrop. ### StoneX Group (SNEX.US) & Financials Financial services network StoneX Group (SNEX.US) logged net operating revenue of **USD 719.7 million** in its fiscal third quarter of 2026, a 47% surge year-over-year, while net income doubled to USD 127.9 million. The company is targeting further market share expansion after its commercial and institutional segments delivered massive 97% and 40% revenue increases, respectively. Although its Q3 EPS of USD 1.00 narrowly missed the USD 1.23 consensus, the top-line acceleration remains pronounced. According to company announcements, StoneX initiated a 3-for-2 stock split to bolster liquidity and partnered with Shinhan Bank to expand its cross-border payments footprint. Alongside StoneX, diversified financial holding XW (XW.US) is similarly recalibrating its operations, adjusting to how shifting interest rates might impact retail trading volumes and derivative margins. ### SenesTech (SNES.US) & Ecolab (ECL.US) Pest control innovator SenesTech (SNES.US) posted its strongest quarter to date in mid-2026. The company reported record Q2 revenue of **USD 770,000**, up 56% sequentially and 23% year-over-year, alongside a record gross margin of 73.6%. The company stated that its active online subscription customer base more than doubled in the quarter, with direct e-commerce revenue reaching USD 511,000 to overtake B2B channels for the first time. Meanwhile, global water and hygiene giant Ecolab (ECL.US) continues to trade with steady momentum this year. The company is leaning on its global industrial and life sciences divisions, fully integrating past acquisitions in the biopharma purification space to secure high-margin, long-term commercial contracts. ### Jet.AI (JTAI.US) & Tech Restructuring Several tech and mobility components are nearing deals to restructure their core operations. Jet.AI (JTAI.US) is transitioning into a pure-play artificial intelligence provider in 2026, divesting its aviation arm to flyExclusive to focus on its consumer-facing CharterGPT app and a new hyperscale data center joint venture. Singapore-based The Growhub (TGHL.US) is expanding its AI research and development efforts, though the supply chain SaaS provider is currently battling a 2026 Nasdaq delisting decision. Separately, Dubai-founded transit software provider Swvl Holdings (SWVL.US) is continuing to rationalize its global footprint, integrating legacy acquisitions across Europe and Latin America as it pushes toward sustainable profitability across its B2B and consumer segments. *This article does not constitute investment advice.* ### Related Stocks - [ECL.US](https://longbridge.com/en/quote/ECL.US.md) - [SWVL.US](https://longbridge.com/en/quote/SWVL.US.md) - [CRL.US](https://longbridge.com/en/quote/CRL.US.md) - [TGHL.US](https://longbridge.com/en/quote/TGHL.US.md) - [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md) - [SNEX.US](https://longbridge.com/en/quote/SNEX.US.md) - [SNES.US](https://longbridge.com/en/quote/SNES.US.md) - [JTAI.US](https://longbridge.com/en/quote/JTAI.US.md) - [RGNT.US](https://longbridge.com/en/quote/RGNT.US.md) ## Related News & Research - [Chairman Of Ecolab Sold $5.00M In Stock](https://longbridge.com/en/news/296633428.md) - [Insider Move at Charles River Labs: Director Cashes In on Company Stock](https://longbridge.com/en/news/296571643.md) - [Charles River Labs director Nancy C. Andrews disposes of 573 common shares worth $163,442.52](https://longbridge.com/en/news/296533503.md) - [RBC Capital Reaffirms Their Buy Rating on Ecolab (ECL)](https://longbridge.com/en/news/296422529.md) - [Grandfield & Dodd LLC Takes Position in Ecolab Inc. $ECL](https://longbridge.com/en/news/296196830.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**